Skip to main content

Table 1 Demographic and clinical characteristics

From: Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes

Characteristic

Exenatide (N = 228)

Insulin Glargine (N = 227)

Total (N = 455)

p value 1

Age (mean, SD)

59.4 (8.9)

57.7 (9.4)

58.5 (9.2)

0.06

Gender (N, % male)

125 (54.8%)

126 (55.5%)

251 (55.2%)

0.92

Ethnicity (N, %)

    

   Caucasian

181 (79.4%)

181 (79.7%)

362 (79.6%)

0.69

   Hispanic

37 (16.2%)

35 (15.4%)

72 (15.8%)

 

   Western Asian

5 (2.2%)

2 (0.9%)

7 (1.5%)

 

   African Descent

1 (0.4%)

3 (1.3%)

4 (0.9%)

 

   Native American

0 (0.0%)

1 (0.4%)

1 (0.2%)

 

   Other

4 (1.8%)

5 (2.2%)

9 (2.0%)

 

Duration of Diabetes in years (mean, SD)

9.7 (5.6)

9.2 (5.9)

9.5 (5.7)

0.21

HBA1c (mean, SD)

8.3% (0.9%)

8.3% (1.0%)

8.3% (1.0%)

0.55

BMI (mean kg/m2, SD)

31.6 (4.5)

31.4 (4.5)

31.5 (4.5)

0.53

  1. 1 P values are for comparisons between the 2 treatment groups. T-tests were used for continuous variables, and Fisher's exact tests were used for categorical variables.